Photocure ASA (PHO) Says AssureMDx Medicare Coverage Remains Expected in 2028

Photocure ASA (PHO) Says AssureMDx Medicare Coverage Remains Expected in 2028

Less than 1 min read

AssureMDx was not included in Novitas’s November 6 LCD, which identifies additional clinical evidence needed for future coverage reconsideration. Photocure continues to expect initial revenue in 2027 and is advancing two studies.

Material Details

| # | Detail | AI Analyst View |

|---|---|---|

| 1 | Medicare coverage timeline remains 2028 | The hoped-for earlier coverage opportunity did not materialize, keeping the original acquisition timeline in place. |

| 2 | AssureMDx excluded from Nov. 6 Novitas LCD | The LCD specifies additional clinical evidence needed before coverage reconsideration. |

| 3 | Initial AssureMDx revenue still expected in 2027 | Photocure says commercial payer and other reimbursement channels remain available despite the Medicare decision. |

| 4 | CMS pricing decision expected before year-end 2026 | A final rate could affect reimbursement economics; the rate takes effect Jan. 1, 2027. |

| 5 | SeARCH involves approximately 1,100 patients | The randomized study is intended to provide clinical-utility evidence for future Medicare coverage reconsideration. |

Context by...